CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 121 enrolled
Drug / intervention
Abatacept Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03841357
NCT03841357Phase 3Completed
CompareCT.gov

An Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

Duke University·interventional·Posted Feb 15, 2019·Updated Jan 23, 2026

In Brief

A Phase 3 clinical trial evaluating Abatacept Injection and Usual Care for Juvenile Idiopathic Arthritis. Completed, enrolled 121 participants across 19 sites.

Detailed Summary

This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJuvenile Idiopathic Arthritis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 15, 2019
Enrollment StartOct 29, 2019
Primary CompletionJan 22, 2025
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.4 years ago

Interventions

Abatacept Injectiondrug

Supplied as a weekly injection via a pre-filled syringe

Usual Careother

Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs